{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T11:41:08Z","timestamp":1781264468537,"version":"3.54.1"},"reference-count":20,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T00:00:00Z","timestamp":1599609600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:p>Stevens\u2010Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life\u2010threatening immune\u2010mediated hypersensitivity reactions. Various drugs, such as Non Steroidal Anti\u2010inflammatory drugs (NSAIDS), allopurinol, anticonvulsants and antibiotics, have been implicated as triggering agent of SJS\/TEN. Levamisole is frequently used as an antihelminthic and as an immunomodulator in cases of nephrotic syndrome. However, levamisole has not been reported as a trigger for SJS\/TEN. The current case describes levamisole\u2010induced TEN in a 15\u2010year\u2010old male who presented to emergency with erythematous lesions, blistering and denudation of skin involving up to 30% of body surface area. Algorithm of drug causality for epidermal necrolysis scoring was applied for causality assessment and a relationship was found to be \u201cpossible\u201d. Immediate withdrawal of levamisole along with a short course of corticosteroids and cyclosporine led to improvement in signs and symptoms. Clinicians should be aware of the possible association of levamisole and SJS\/TEN.<\/jats:p>","DOI":"10.1111\/bcp.14533","type":"journal-article","created":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T18:04:27Z","timestamp":1599069867000},"page":"1574-1577","source":"Crossref","is-referenced-by-count":5,"title":["Levamisole induced toxic epidermal necrolysis: A case report"],"prefix":"10.1111","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7984-9351","authenticated-orcid":false,"given":"Rachna","family":"Rohilla","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Postgraduate Institute of Medical Education and Research DM\u2010Resident Clinical Pharmacology  Chandigarh India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arihant","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Postgraduate Institute of Medical Education and Research  Chandigarh India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,9,9]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.4103\/jmms.jmms_41_17"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.5114\/ceji.2016.63122"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13312-014-0419-7"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00865500"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1993.01680220104023"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.2332\/allergolint.55.9"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(96)00035-2"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780100408"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1990.01670250049006"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1991.01680050083008"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.01.031"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1990.01670250043005"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0165933"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512143332404"},{"key":"e_1_2_8_16_1","unstructured":"The use of the WHO\u2010UMC system for standardised case causality assessment.https:\/\/www.who.int\/medicines\/areas\/quality_safety\/safety_efficacy\/WHOcausality_assessment.pdf. Accessed on 20 March 2020."},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.14581\/jer.16016"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.252"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-5-39"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.09.162"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8060860"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14533","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.14533","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14533","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T11:54:12Z","timestamp":1693655652000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.14533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,9]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1111\/bcp.14533"],"URL":"https:\/\/doi.org\/10.1111\/bcp.14533","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,9]]}}}